Cystagon
Generic: CYSTEAMINE BITARTRATE
Basic Information
Manufacturer
Mylan Pharmaceuticals Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
ORAL
FDA Set ID
f495b76d-96c6-48e5-8fa3-30a4336628eb
Indications & Usage
INDICATIONS AND USAGE CYSTAGON ® is indicated for the management of nephropathic cystinosis in children and adults.
Warnings
WARNINGS If a skin rash develops, CYSTAGON ® should be withheld until the rash clears.
CYSTAGON ® may be restarted at a lower dose under close supervision, then slowly titrated to the therapeutic dose.
If a severe skin rash develops such as erythema multiforme bullosa or toxic epidermal necrolysis, CYSTAGON ® should not be readministered.
CNS symptoms such as seizures, lethargy, somnolence, depression, and encephalopathy have been associated with cysteamine.
If CNS symptoms develop, the patient should be carefully evaluated and the dose adjusted as necessary.
Neurological complications have been described in some cystinotic patients not on cysteamine treatment.
This may be a manifestation of the primary disorder.
Patients should not engage in hazardous activities until the effects of CYSTAGON ® on mental performance are known.
Gastrointestinal ulceration and bleeding have been reported in patients receiving cysteamine bitartrate.
Physicians should remain alert for signs of ulceration and bleeding and should inform patients and/or guardians about the signs and symptoms of serious G.I.
toxicity and what steps to take if they occur.
Post-marketing reports include one report of interstitial nephritis with early renal failure.
A causal relationship between this event and cysteamine bitartrate therapy has not been established.
CYSTAGON ® may be restarted at a lower dose under close supervision, then slowly titrated to the therapeutic dose.
If a severe skin rash develops such as erythema multiforme bullosa or toxic epidermal necrolysis, CYSTAGON ® should not be readministered.
CNS symptoms such as seizures, lethargy, somnolence, depression, and encephalopathy have been associated with cysteamine.
If CNS symptoms develop, the patient should be carefully evaluated and the dose adjusted as necessary.
Neurological complications have been described in some cystinotic patients not on cysteamine treatment.
This may be a manifestation of the primary disorder.
Patients should not engage in hazardous activities until the effects of CYSTAGON ® on mental performance are known.
Gastrointestinal ulceration and bleeding have been reported in patients receiving cysteamine bitartrate.
Physicians should remain alert for signs of ulceration and bleeding and should inform patients and/or guardians about the signs and symptoms of serious G.I.
toxicity and what steps to take if they occur.
Post-marketing reports include one report of interstitial nephritis with early renal failure.
A causal relationship between this event and cysteamine bitartrate therapy has not been established.
Adverse Reactions
ADVERSE REACTIONS In three clinical trials, cysteamine or phosphocysteamine have been administered to 246 children with cystinosis.
Causality of side effects is sometimes difficult to determine because adverse effects may result from the underlying disease.
The most frequent adverse reactions seen involve the gastrointestinal and central nervous systems.
These are especially prominent at the initiation of cysteamine therapy.
Temporarily suspending treatment, then gradual re-introduction may be effective in improving tolerance.
Adverse reactions were not collected systematically in the NCCS, but were often listed by investigators.
The following rates may therefore be underestimated.
The most common events (> 5%) were vomiting 35%, anorexia 31%, fever 22%, diarrhea 16%, lethargy 11%, and rash 7%.
Less common adverse events are: Body as a whole: Dehydration.
Cardiovascular: Hypertension.
Digestive: Nausea, bad breath, abdominal pain, dyspepsia, constipation, gastroenteritis, duodenitis, gastrointestinal ulceration and bleeding.
Central Nervous System: Somnolence, encephalopathy, headache, seizures, ataxia, confusion, tremor, hyperkinesia, decreasing hearing, dizziness, jitteriness.
Psychiatric: Nervousness, abnormal thinking, depression, emotional lability, hallucinations, nightmares.
Integumentary: Urticaria.
Urogenital: Interstitial nephritis, renal failure (see WARNINGS ).
Clinical Laboratory: Abnormal liver function, anemia, leukopenia.
Adverse reactions or intolerance leading to cessation of treatment occurred in 8% of patients in the U.S.
Studies.
Withdrawals due to intolerance, vomiting associated with medication, anorexia, lethargy, and fever appeared dose related, occurring more frequently in those patients receiving 1.95 grams/m 2 /day as compared to 1.30 grams/m 2 /day.
Dose in Grams/m 2 /day 1.30 ( n = 42 ) % 1.95 ( n = 51 ) % Vomiting Considered Related to Medicine 31 67 Anorexia 33 51 Lethargy 17 27 Diarrhea 31 31 Fever 28 45 Sudden deaths have been reported in this disease state.
Post-marketing surveillance Benign intracranial hypertension (or pseudotumor cerebri; PTC) with papilledema; skin lesions, molluscoid pseudotumors, skin striae, skin fragility; joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture and scoliosis have been reported (see PRECAUTIONS ).
Causality of side effects is sometimes difficult to determine because adverse effects may result from the underlying disease.
The most frequent adverse reactions seen involve the gastrointestinal and central nervous systems.
These are especially prominent at the initiation of cysteamine therapy.
Temporarily suspending treatment, then gradual re-introduction may be effective in improving tolerance.
Adverse reactions were not collected systematically in the NCCS, but were often listed by investigators.
The following rates may therefore be underestimated.
The most common events (> 5%) were vomiting 35%, anorexia 31%, fever 22%, diarrhea 16%, lethargy 11%, and rash 7%.
Less common adverse events are: Body as a whole: Dehydration.
Cardiovascular: Hypertension.
Digestive: Nausea, bad breath, abdominal pain, dyspepsia, constipation, gastroenteritis, duodenitis, gastrointestinal ulceration and bleeding.
Central Nervous System: Somnolence, encephalopathy, headache, seizures, ataxia, confusion, tremor, hyperkinesia, decreasing hearing, dizziness, jitteriness.
Psychiatric: Nervousness, abnormal thinking, depression, emotional lability, hallucinations, nightmares.
Integumentary: Urticaria.
Urogenital: Interstitial nephritis, renal failure (see WARNINGS ).
Clinical Laboratory: Abnormal liver function, anemia, leukopenia.
Adverse reactions or intolerance leading to cessation of treatment occurred in 8% of patients in the U.S.
Studies.
Withdrawals due to intolerance, vomiting associated with medication, anorexia, lethargy, and fever appeared dose related, occurring more frequently in those patients receiving 1.95 grams/m 2 /day as compared to 1.30 grams/m 2 /day.
Dose in Grams/m 2 /day 1.30 ( n = 42 ) % 1.95 ( n = 51 ) % Vomiting Considered Related to Medicine 31 67 Anorexia 33 51 Lethargy 17 27 Diarrhea 31 31 Fever 28 45 Sudden deaths have been reported in this disease state.
Post-marketing surveillance Benign intracranial hypertension (or pseudotumor cerebri; PTC) with papilledema; skin lesions, molluscoid pseudotumors, skin striae, skin fragility; joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture and scoliosis have been reported (see PRECAUTIONS ).